HK1161133A1 - Pharmaceutical formulations of potassium atp channel openers and uses thereof atp - Google Patents

Pharmaceutical formulations of potassium atp channel openers and uses thereof atp

Info

Publication number
HK1161133A1
HK1161133A1 HK12101988.8A HK12101988A HK1161133A1 HK 1161133 A1 HK1161133 A1 HK 1161133A1 HK 12101988 A HK12101988 A HK 12101988A HK 1161133 A1 HK1161133 A1 HK 1161133A1
Authority
HK
Hong Kong
Prior art keywords
atp
channel openers
pharmaceutical formulations
potassium
outcomes
Prior art date
Application number
HK12101988.8A
Other languages
English (en)
Chinese (zh)
Inventor
Neil M Cowen
Kenneth B Kashkin
Original Assignee
Essentialis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Essentialis Inc filed Critical Essentialis Inc
Publication of HK1161133A1 publication Critical patent/HK1161133A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
HK12101988.8A 2004-08-25 2012-02-28 Pharmaceutical formulations of potassium atp channel openers and uses thereof atp HK1161133A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US60408504P 2004-08-25 2004-08-25
US62421904P 2004-11-03 2004-11-03
US65457105P 2005-02-22 2005-02-22
US66891205P 2005-04-06 2005-04-06
EP10159141A EP2208496A1 (en) 2004-08-25 2005-08-25 Pharmaceutical formulations of potassium ATP channel openers and uses thereof
EP05791600A EP1781265B1 (en) 2004-08-25 2005-08-25 Pharmaceutical formulations of potassium atp channel openers and uses thereof

Publications (1)

Publication Number Publication Date
HK1161133A1 true HK1161133A1 (en) 2012-08-24

Family

ID=36000625

Family Applications (2)

Application Number Title Priority Date Filing Date
HK12101988.8A HK1161133A1 (en) 2004-08-25 2012-02-28 Pharmaceutical formulations of potassium atp channel openers and uses thereof atp
HK16102894.5A HK1214945A1 (zh) 2004-08-25 2016-03-14 通道開放劑的藥物製劑及其應用

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16102894.5A HK1214945A1 (zh) 2004-08-25 2016-03-14 通道開放劑的藥物製劑及其應用

Country Status (12)

Country Link
US (6) US20060051418A1 (ja)
EP (3) EP2404605B1 (ja)
JP (1) JP2008510835A (ja)
CN (1) CN104958270A (ja)
AT (1) ATE463249T1 (ja)
AU (2) AU2005280058B2 (ja)
CA (1) CA2578224A1 (ja)
DE (1) DE602005020462D1 (ja)
DK (1) DK1781265T3 (ja)
ES (2) ES2539969T3 (ja)
HK (2) HK1161133A1 (ja)
WO (1) WO2006026469A2 (ja)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1784221B (zh) 2003-04-29 2010-07-07 奥雷西根治疗公司 影响体重减轻的组合物
CA2578224A1 (en) * 2004-08-25 2006-03-09 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof
US20070026079A1 (en) * 2005-02-14 2007-02-01 Louis Herlands Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
US9757384B2 (en) 2005-04-06 2017-09-12 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
US20060243696A1 (en) * 2005-04-27 2006-11-02 Spada Lon T Tip design for reducing capillary leakage and water loss for plastic container closures
MX337422B (es) 2005-11-22 2016-03-04 Orexigen Therapeutics Inc Composiciones y metodos para incrementar la sencibilidad a la insulina.
US20070161661A1 (en) * 2005-12-28 2007-07-12 Mellican Sean M Crystalline N-(4-(4-ammoniumthieno[2,3-d]pyrimidin-5-yl)phenyl)-N'-(2-fluoro-5-(trifluoromethyl)phenyl)urea ethanesulfonate
AU2006335153B2 (en) 2006-01-05 2012-03-15 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
US20090130206A1 (en) * 2006-05-09 2009-05-21 Umesh Nandkumar Khatavkar Controlled Release Compositions of an Antidepressant Agent
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
KR20140088619A (ko) 2006-11-09 2014-07-10 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
JP2010532383A (ja) * 2007-07-02 2010-10-07 エッセンシャリス，インク． カリウムａｔｐチャネル開口薬の塩およびその使用
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
EP3578177A1 (en) 2008-09-02 2019-12-11 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
WO2010093243A1 (en) 2009-02-12 2010-08-19 Coöperatieve Mirzorg U.A., Arnhem Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
EP3563842A1 (en) 2009-04-29 2019-11-06 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
RU2538691C2 (ru) 2009-04-29 2015-01-10 Амарин Фарма, Инк. Стабильные фармацевтические композиции и способы их применения
LT3318255T (lt) 2009-06-15 2021-05-25 Amarin Pharmaceuticals Ireland Limited Kompozicijos ir būdai, skirti insulto gydymui pacientui kartu su statinų terapija
CA2775339C (en) 2009-09-23 2017-03-28 Amarin Corporation Plc Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
KR101841442B1 (ko) * 2010-01-11 2018-03-23 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
EP2422787A1 (en) * 2010-08-17 2012-02-29 Neurotec Pharma, S.L. Diazoxide for use in the treatment of amyotrophic lateral sclerosis (als)
BR112013005434A2 (pt) 2010-09-23 2016-06-07 Abbott Lab novo mono-hidrato de derivados de aza-adamantano
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
WO2013130411A1 (en) 2012-02-27 2013-09-06 Essentialis, Inc. Salts of potassium atp channel openers and uses thereof
CA2875056C (en) 2012-06-06 2024-03-26 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
EP4342546A3 (en) 2012-06-29 2024-05-22 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US20140221358A1 (en) * 2013-02-06 2014-08-07 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and diazoxide and methods of use thereof
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20140364367A1 (en) * 2013-06-08 2014-12-11 Sedogen, Llc Methods of treating prader willi syndrome and conditions associated with low basal metabolic rate or hyperphagia using a katp channel opener
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10981951B2 (en) 2014-01-31 2021-04-20 Mayo Foundation For Medical Education And Research Therapeutics for the treatment of glaucoma
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
WO2016077629A1 (en) * 2014-11-14 2016-05-19 Essentialis, Inc. Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
US10413526B2 (en) * 2015-03-31 2019-09-17 Kolinpharma S.P.A. Composition for the treatment of neuropathies and/or neuropathic pain
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
FI4056176T3 (fi) 2018-09-24 2024-05-30 Amarin Pharmaceuticals Ie Ltd Menetelmät kardiovaskulaaristen tapahtumien riskin pienentämiseksi tutkittavassa
US20240299405A1 (en) * 2020-05-28 2024-09-12 Hangzhou Qian Biotechnology Ltd Application of atp potassium channel modifier in preparation of anti-diabetic nephropathy drug
WO2022076746A1 (en) * 2020-10-09 2022-04-14 Scienture, Inc. Losartan liquid formulations and methods of use
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
WO2024086252A1 (en) * 2022-10-18 2024-04-25 Rhythm Pharmaceuticals, Inc. Novel atp-sensitive potassium channel potentiators, their preparation and use
CN116236451B (zh) * 2023-04-18 2024-04-19 淄博市中心医院 一种阿卡波糖片、制备方法及用途

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3269906A (en) * 1966-08-30 Imino-j,x-dihydro-l,z,x-benzothiadiazine- i,i-dioxides
US2678311A (en) * 1952-05-07 1954-05-11 Delmar Chem Theophylline salts
US2986573A (en) 1961-01-18 1961-05-30 Schering Corp Method for the treatment of hypertension
GB982072A (en) 1960-09-19 1965-02-03 Scherico Ltd Benzothiadiazine-1,1-dioxides and processes for their manufacture
US3304228A (en) * 1961-06-26 1967-02-14 Schering Corp Derivatives of 1, 2, 4-benzothiadiazine-1, 1-dioxides
US3265573A (en) * 1962-07-27 1966-08-09 Squibb & Sons Inc Benzothiadiazinesulfonamide-1, 1-dioxide composition
US3345365A (en) * 1964-03-31 1967-10-03 Schering Corp Novel 1, 2, 4-benzothiadiazine-1, 1-dioxide derivatives
US3431138A (en) * 1967-07-14 1969-03-04 American Cyanamid Co Method for coating pharmaceutical forms with methyl cellulose
JPS5248889B2 (ja) 1973-10-29 1977-12-13
ES442149A1 (es) * 1974-10-29 1977-04-01 Dainippon Pharmaceutical Co Procedimiento para preparar derivados de 1,2,4-benzotiadia- zino-1,1-dioxido.
US4184039A (en) * 1977-12-01 1980-01-15 Paul Finkelstein Benzothiadiazine 1, 1-dioxides
DE2757925A1 (de) 1977-12-24 1979-06-28 Bayer Ag Diazacyclo-1.2.4-benzothiadizine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
JPS5995212A (ja) 1982-11-23 1984-06-01 Nitto Electric Ind Co Ltd 基剤組成物及び外用医薬組成物
DE3530857A1 (de) * 1985-08-29 1987-03-05 Hoechst Ag Verfahren zur herstellung von niedrigviskosen celluloseethern
GB8601204D0 (en) 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
GB2186485B (en) 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
DE68917946T2 (de) 1988-01-29 1995-01-05 Peter H Proctor Haarwachstumanregung mit Nitroxyd und anderen Radikalen.
US5063208A (en) * 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
US6361795B1 (en) 1989-09-05 2002-03-26 Alza Corporation Method for lowering blood glucose
US5284845A (en) 1991-03-14 1994-02-08 Paulsen Elsa P Use of oral diazoxide for the treatment of disorders in glucose metabolism
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
US5378704A (en) * 1992-04-15 1995-01-03 E. R. Squibb & Sons, Inc. Non-peptidic angiotensin-II-receptor-antagonists
FR2690160A1 (fr) 1992-04-15 1993-10-22 Rhone Poulenc Rorer Sa Application de dérivés d'acide 2H-1,2,4-benzothiadiazine-1,1-dioxyde-3-carboxylique à la préparation de médicaments, les produits nouveaux, leur préparation et les médicaments les contenant.
US5356775A (en) * 1992-07-29 1994-10-18 Brigham & Women's Hospital Primary structure for functional expression from complementary DNA of a mammalian ATP-sensitive potassium channel
US5629045A (en) * 1992-09-17 1997-05-13 Richard L. Veech Biodegradable nosiogenic agents for control of non-vertebrate pests
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
FR2703051B1 (fr) 1993-03-26 1995-04-28 Adir Nouvelles pyridothiadiazines, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent.
US5747278A (en) * 1993-05-21 1998-05-05 California Institute Of Technology DNA encoding inward rectifier, G-protein activated, mammalian, potassium KGA channel and uses thereof
US5965620A (en) * 1993-07-23 1999-10-12 Vide Pharmaceuticals Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure
EP0705298B1 (en) * 1993-12-01 2002-03-27 Bioartificial Gel Technologies Inc. Albumin based hydrogel
US5744594A (en) * 1994-02-08 1998-04-28 Oregon Health Sciences University DNA encoding ATP-sensitive potassium channel genes
US5399359A (en) * 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
DE69632569T2 (de) * 1995-06-09 2005-08-18 Euroceltique S.A. Formulierungen und verfahren für eine verlängerte lokalanästhesie
US6225310B1 (en) * 1996-01-17 2001-05-01 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
US6309855B1 (en) * 1996-02-08 2001-10-30 Centre National De La Recherche (Cnrs) Family of mammalian potassium channels, their cloning and their use, especially for the screening of drugs
US5885980A (en) * 1996-06-25 1999-03-23 Enrique G. Gutierrez Composition and method for treating diabetes
WO1998010786A2 (en) 1996-09-12 1998-03-19 Yarom Cohen Pharmaceutical composition for the treatment of syndrome x of reaven
PL191399B1 (pl) * 1996-10-28 2006-05-31 Gen Mills Inc Sposób kapsułkowania lub osadzania składnika w osnowie w procesie ciągłym, sposób kapsułkowania i/lub osadzania składników w osnowie opartej na węglowodanach, sposób kapsułkowania i/lub osadzania składników w osnowie oraz kapsułka
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
CN1278738A (zh) * 1997-11-10 2001-01-03 久光制药株式会社 药剂用缓释和含有该缓释剂的缓释性药物组合物
AU5134699A (en) * 1998-07-24 2000-02-14 Andrix Pharmaceuticals, Inc. Granule modulating hydrogel system
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197976B1 (en) * 1998-12-14 2001-03-06 Syntex (U.S.A.) Llc Preparation of ketorolac
US6329367B1 (en) * 1998-12-18 2001-12-11 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
EP1140187B1 (en) * 1998-12-23 2003-09-03 G.D. Searle LLC. Combinations of an ibat inhibitor and a mtp inhibitor for cardiovascular indications
CH693625A5 (it) * 1999-02-18 2003-11-28 Inpharma Sa Composizioni farmaceutiche contenenti composti ad attività promotrice di assorbimento di principi attivi.
US20020119933A1 (en) * 2000-07-28 2002-08-29 Butler Terri L. Compositions and methods for improving cardiovascular function
US6197765B1 (en) * 1999-06-08 2001-03-06 Pnina Vardi Use of diazoxide for the treatment of metabolic syndrome and diabetes complications
US20030220329A1 (en) * 1999-09-17 2003-11-27 Duke University Method of improving beta-adrenergic receptor function
US6436944B1 (en) 1999-09-30 2002-08-20 Pfizer Inc. Combination effective for the treatment of impotence
MXPA02003463A (es) * 1999-10-04 2004-09-10 R Bernstein Lawrence Complejos de galio de 3-hidroxi-4-pironas para tratar la infeccion por procariontes intracelulares, virus de adn y retrovirus.
US6313112B1 (en) * 1999-10-22 2001-11-06 Wake Forest University Methods of protecting neuronal function
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
FR2801587B1 (fr) * 1999-11-30 2002-01-11 Adir Nouveaux derives de benzothiadiazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20020192302A1 (en) * 1999-12-16 2002-12-19 Tsung-Min Hsu Transdermal and topical administration of antidepressant drugs using basic enhancers
DE10012199A1 (de) * 2000-03-13 2001-09-20 Haarmann & Reimer Gmbh Eingekapselte Substanzen mit kontrollierter Freisetzung
GB2361185A (en) * 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
US6635277B2 (en) * 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
AU2001265840A1 (en) * 2000-06-26 2002-01-08 Novo-Nordisk A/S Use of potassium channel agonists for reducing fat food comsumption
WO2002002320A1 (en) * 2000-06-30 2002-01-10 Microcoating Technologies, Inc. Polymer coatings
CA2775616C (en) 2000-08-04 2013-09-17 Takeda Pharmaceutical Company Limited Salts of benzimidazole compound and application thereof
AU2001294192A1 (en) * 2000-10-06 2002-04-22 Takeda Chemical Industries Ltd. Solid preparations
AU2002213174A1 (en) * 2000-10-13 2002-04-22 Massaharu Akao Treatment of apoptotic cell death
GB0025473D0 (en) * 2000-10-17 2000-11-29 Pfizer Ltd Pharmaceutical combinations
EP1345916A1 (en) * 2000-12-20 2003-09-24 Glaxo Group Limited Substituted oxazoles and thiazoles as hppar alpha agonists
WO2002050085A1 (en) 2000-12-21 2002-06-27 Novo Nordisk A/S A new process for preparing fused 1,2,4-thiadiazine derivatives
DE60235535D1 (de) * 2001-01-19 2010-04-15 Inst Pharm & Toxicology Amms Aminderivat mit kaliumkanalregulierender funktion, dessen herstelung und verwendung
TW478039B (en) * 2001-04-09 2002-03-01 Promos Technologies Inc Phase shift alignment system
WO2002088378A2 (en) * 2001-04-13 2002-11-07 Millennium Pharmaceuticals, Inc. 66784, a novel human potassium channel and uses therefor
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
CA2414912A1 (en) * 2001-12-20 2003-06-20 University Of Saskatchewan Technologies Inc. Pleurotus extract and use in treating hypertension
DE10209979A1 (de) * 2002-03-07 2003-09-25 Ratiopharm Gmbh Arzneimittel mit Cholesterolspiegel-senkenden Wirkstoffen mit zeitverzögerter Wirkstofffreisetzung
WO2003090742A1 (en) * 2002-04-26 2003-11-06 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising a lipase inhibitor and glucomannan
US6960346B2 (en) * 2002-05-09 2005-11-01 University Of Tennessee Research Foundation Vehicles for delivery of biologically active substances
WO2003099801A1 (en) 2002-05-24 2003-12-04 Smithkline Beecham Corporation Novel anti-infectives
WO2003103606A2 (en) 2002-06-10 2003-12-18 Metabolex, Inc. Methods and compositions for treating and diagnosing diabetes
AU2003232171A1 (en) 2002-06-14 2003-12-31 Novo Nordisk A/S Combined use of a modulator of cd3 and a beta cell resting compound
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20040097492A1 (en) * 2002-11-01 2004-05-20 Pratt John K Anti-infective agents
US7902203B2 (en) * 2002-11-01 2011-03-08 Abbott Laboratories, Inc. Anti-infective agents
US20050075331A1 (en) * 2003-10-06 2005-04-07 Pratt John K. Anti-infective agents
WO2004043534A1 (en) * 2002-11-12 2004-05-27 Collegium Pharmaceutical, Inc. Inertial drug delivery system
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US7311727B2 (en) * 2003-02-05 2007-12-25 Board Of Trustees Of The University Of Arkansas Encased stent
CL2004000366A1 (es) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
US20040204472A1 (en) 2003-03-04 2004-10-14 Pharmacia Corporation Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
US20040229803A1 (en) * 2003-04-22 2004-11-18 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
FR2854634B1 (fr) 2003-05-05 2005-07-08 Servier Lab Nouveaux derives de thiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4220314B2 (ja) 2003-06-12 2009-02-04 株式会社テクノ菱和 装着型軟ｘ線検出器
US7378414B2 (en) * 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
WO2005025511A2 (en) * 2003-09-10 2005-03-24 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
EP1782812A1 (en) * 2004-06-23 2007-05-09 Neurotec Pharma, S.L. Compounds for the treatment of inflammation of the central nervous system
PL1789021T3 (pl) * 2004-08-13 2012-04-30 Boehringer Ingelheim Int Preparat tabletkowy o przedłużonym uwalnianiu zawierający pramipeksol lub jego farmaceutycznie dopuszczalną sól
CA2578224A1 (en) 2004-08-25 2006-03-09 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof
JP2008517976A (ja) * 2004-10-25 2008-05-29 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ１カンナビノイド受容体拮抗薬及びカリウムチャンネルオープナーから成る、真性糖尿病１型、肥満及び関連症状の治療用の医薬組成物
FR2877338B1 (fr) * 2004-11-03 2007-01-26 Servier Lab Nouveaux derives de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20060263805A1 (en) * 2005-03-16 2006-11-23 Andre Terzic Diagnosing and treating potassium channel defects
US9757384B2 (en) 2005-04-06 2017-09-12 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
AU2006335153B2 (en) * 2006-01-05 2012-03-15 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
JP2007294934A (ja) * 2006-03-30 2007-11-08 Canon Inc 計測方法及び装置、露光装置及び方法、調整方法、並びに、デバイス製造方法
US20070254863A1 (en) * 2006-04-27 2007-11-01 Jochen Antel Use of CBx cannabinoid receptor modulators as potassium channel modulators
JP2010532383A (ja) 2007-07-02 2010-10-07 エッセンシャリス，インク． カリウムａｔｐチャネル開口薬の塩およびその使用
US20120238554A1 (en) 2007-07-02 2012-09-20 Cowen Neil M Salts of potassium atp channel openers and uses thereof
WO2013130411A1 (en) 2012-02-27 2013-09-06 Essentialis, Inc. Salts of potassium atp channel openers and uses thereof
WO2016077629A1 (en) 2014-11-14 2016-05-19 Essentialis, Inc. Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome

Also Published As

Publication number Publication date
EP1781265B1 (en) 2010-04-07
DK1781265T3 (da) 2010-08-02
ES2539969T3 (es) 2015-07-07
DE602005020462D1 (de) 2010-05-20
US9782416B2 (en) 2017-10-10
AU2005280058B2 (en) 2010-09-02
US20140350001A1 (en) 2014-11-27
US20060051418A1 (en) 2006-03-09
AU2010246520B2 (en) 2011-11-03
WO2006026469A2 (en) 2006-03-09
EP2404605B1 (en) 2015-04-22
AU2005280058A1 (en) 2006-03-09
AU2010246520A1 (en) 2010-12-23
WO2006026469A3 (en) 2006-08-03
EP1781265A4 (en) 2009-07-15
JP2008510835A (ja) 2008-04-10
EP1781265A2 (en) 2007-05-09
US20090149451A1 (en) 2009-06-11
ATE463249T1 (de) 2010-04-15
EP2208496A1 (en) 2010-07-21
CN104958270A (zh) 2015-10-07
US20090148525A1 (en) 2009-06-11
CA2578224A1 (en) 2006-03-09
US20200237772A1 (en) 2020-07-30
US20180280405A1 (en) 2018-10-04
EP2404605A1 (en) 2012-01-11
ES2342090T3 (es) 2010-07-01
HK1214945A1 (zh) 2016-08-12

Similar Documents

Publication Publication Date Title
HK1214945A1 (zh) 通道開放劑的藥物製劑及其應用
HK1117078A1 (en) Salts of potassium atp channel openers and uses thereof
MX2021003982A (es) Activador del canal de katp para usarse en el incremento de la masa muscular del miembro inferior en un sujeto que padece el síndrome de smith-magenis (sms).
IL273765A (en) Combinations and forms of administration of therapeutic agents and combined treatment
EP1611880A3 (en) Pharmaceutical formulations for the safe administration of drugs used in the treatment of drug addiction
WO2005070081A3 (en) Methods of using zonisamide as an adjunctive therapy for partial seizures
WO2005070080A3 (en) Methods of using zonisamide as an adjunctive therapy for partial seizures
WO2007023408A3 (en) 4d image-based planning methods and apparatus for targeted therapy
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
DK2043637T3 (da) Fremgangsmåder og medikamenter til administrering af ibuprofen
NO20080244L (no) Doseringsstyring for prasugrel
WO2004043378A3 (en) Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
WO2006055886A3 (en) Method for customized dispensing of variable dose drug combination products for individualizing of therapies
WO2005070077A3 (en) Methods of using zonisamide as an adjunctive therapy for partial seizures
WO2005087255A3 (en) Method of optimizing treatment with interferon-tau
Rappold et al. Treatment modification in HIV-Infected individuals starting antiretroviral therapy between 2011 and 2014
WO2007067753A3 (en) Methods of reducing side effects in cancer therapy
TW200500073A (en) Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof
Manias Practices and predictions of analgesic interventions for adults undergoing painful procedures
RU2004107473A (ru) Способ терапии хронического перенапряжения организма спортсмена
Garrison et al. Successful implementation of pharmacy-driven darbepoetin alfa guidelines for treatment of chemotheraphy-related anemia at Seattle Cancer Care Alliance, University of Washington and Harborview Medical Centers
UA3848U (uk) Спосіб активації процесів метаболізму у високопродуктивних корів
RU2003124139A (ru) Способ пролонгированной лекарственной терапии
UA4355U (uk) Спосіб комплексного лікування пізнього радіаційного ентероколіту в поєднанні з ішемічною хворобою серця у онкологічних хворих